Skip to main content
21, Apr 2025

New blood test to predict antibody-mediated rejection to be presented at World Transplant Congress

SAN FRANCISCO — August, 2025. Antibody-mediated rejection causes severe graft injury and graft loss.

Read more
23, Oct 2022

Rapid six-hour test panel to predict CMV infection and transplant rejection

Plexision, a biotechnology company, is offering the first blood test panel capable of reporting the risk of cytomegal

Read more
26, May 2021

T-cell and antibody immunity after COVID-19 vaccination in healthy and immunocompromised

An exploratory study reported on May 23, 2021, in MedRxiv described changes in T-cell and antibody immunity after mRN

Read more
6, May 2021

Impaired T-cell and antibody responses after COVID-19 infection in transplant recipients

In transplant recipients on chronic immunosuppression, COVID-19 infection is associated with impaired T-cell and anti

Read more
19, Mar 2021

Transplant recipients show impaired antibody responses to the first mRNA vaccine dose.

On March 15, 2021, Boyarski et al.

Read more
28, Feb 2021

COVID-19 Update: The first non-mRNA vaccine
  • On February 27, the FDA issued an Emergency Use Authorization for Johnson and Johnson’s non-mRNA vaccine.
Read more
5, Jan 2021

COVID-19 Vaccines: Authorized for Emergency Use

Latest Updates: (01/18/2021)

Read more
31, Dec 2020

Recurrent Illness and the Burden of COVID-19

Recurring symptoms lasting several months may require ongoing treatment in some patients who have experienced COVID-1

Read more
29, Dec 2020

COVID-19 variant: Early data

A new variant of the coronavirus that causes COVID-19 has been reported in the UK.

Read more


Kidney Transplant Surveillance with the Pleximark blood test

Submitted by osutra_adm1n on 13, Dec 2020

Rohan et al at the Medical University of South Carolina in Charleston, SC, recently evaluated the first 22 renal transplant recipients to receive clinical immune monitoring with donor-reactive T-cytotoxic memory cells. This cell type determines the likelihood of rejection in the Pleximark test. Increased donor-reactivity was associated with renal allograft rejection with a sensitivity of 83% and a negative predictive value of 91%. This increased reactivity also correlated with (r=0.453, p=0.03) with graft dysfunction measured with serum creatinine…....

Subscribe to

About

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.

Contact